Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Scancell Holdings "well-financed" and continuing to pursue deals

Scancell Holdings PLC

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF)'s chief executive Professor Lindy Durrant speaks to Thomas Warner from Proactive to provide an update on the clinical stage biopharmaceutical company's progress and financial position. Durrant starts by highlighting that Scancell has "plenty of money" before going into more detail about what's been happening with its two lead compounds, SCIB1 and Modi-1. She also touches on progress in the relationship with Genmab since signing a commercial licensing agreement last year, and clarifies that Scancell is continuing to pursue other such deals: "We've just signed an evaluation with a new company... and we're in current discussions with a second company about another potential deal." She adds that the company is "well financed" with a runway extending into the second half of 2024, but makes it clear that the continued emergence of promising clinical data could make a fundraise necessary - saying that "clearly a company of our size always needs to think about that as we go forward." Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

July 11, 2023 06:51 AM Eastern Daylight Time

Video

HLHS Is A Rare And Serious Congenital Heart Disease With A 33% Neonatal Death Rate — Could Longeveron’s Lomecel-B Improve Outcomes?

LONGEVERON INC.

By David Willey, Benzinga Longeveron (NASDAQ: LGVN) announced the results of its phase 1 trial for infants with a rare and serious congenital heart disease (CHD), known as hypoplastic left heart syndrome. The Company, which is now conducting its phase 2a trial, is a clinical-stage biotechnology firm working to develop treatments for rare diseases and age-related and life-threatening conditions. CHDs are the most common congenital disease, affecting around 40,000 babies born in the U.S. every year. While many CHDs can be medically managed, 25% are much more serious and often require immediate surgical intervention. As a result, CHDs are a leading cause of death for infants. An increase in critical CHDs is powering growth in the newborn screening market, which is expected to reach $3 billion in 2031, growing at a compound annual growth rate (CAGR) of 11.2% from 2021 to 2031. Longeveron is working to develop a treatment for one of the most severe CHDs, hypoplastic left heart syndrome (HLHS). HLHS is a very serious heart defect in which the left side of the heart is underdeveloped and unable to provide normal blood circulation through the heart. HLHS accounts for 2-3% of all CHDs, with around 1 in every 3,800 US babies being born with HLHS every year. HLHS is considered a rare pediatric disease, and Longeveron has received a Rare Pediatric Disease Designation from the FDA for Lomecel-B. Children with HLHS require 3 different open-heart surgeries to allow survival, but even with these surgeries, many of the children will go on to need a heart transplant. Despite the increasing sophistication of these surgeries, the neonatal death rate for HLHS is 33%, and the 5-year survival rate is only 50-60%. HLHS treatments are also expensive, costing the average neonatal hospital stay over $280,000. Longeveron Completes Phase 1, Starts Phase 2 Longeveron is focusing on HLHS with its cell-based therapy, the drug candidate, Lomecel-B ™. This drug, which is made from medicinal signaling cells (MSCs), will be a potential combinational therapy delivered via intracardiac injection during the second neonatal open-heart surgery. The goal of adding Lomecel-B ™ is to boost the function of the single ventricle, with the ultimate goal of reducing the need for transplantation and possibly increasing survival. The Company concluded its open-label phase 1 trial on 10 patients, aged four to five months, and followed these children for a period ranging from 3.5-5 years. The one-year trial’s results were published in the European Heart Journal Open, and revealed that all the patients had responded well to the procedure and were transplant-free one year after the treatment. None of the babies experienced a pre-defined safety endpoint, and the procedure was well tolerated. “This data supports our hope that Lomecel-B TM has the potential to alter the treatment landscape for patients with HLHS, a rare and life-threatening congenital heart disease,” said Wa’el Hashad, Longeveron’s Chief Executive Officer. “Notably, the procedure appeared to be generally safe and well-tolerated in the babies undergoing heart surgery in the first 6 months of life. The study provisionally shows suggestions of possible improvement in measures of cardiac function, findings that are presently being tested in our ongoing controlled and randomized Phase 2 study.” Dr. Joshua Hare, who co-authored the European Heart article, is the co-founder of Longeveron and is an established leader in the field of cardiac treatment. He recently published a second article on HLHS, which described the current status of treatments for HLHS and outlined the future direction of the field. The article identifies Lomecel-B ™ as the first-in-class MSC therapy to reach the trial stage. Longeveron is moving forward with its phase 2 trial in partnership with the National Heart, Lung, and Blood Institute and the trial is being conducted at 8 leading pediatric cardiac surgical programs. This randomized, blind, controlled study with 38 patients will evaluate Lomecel-B’s ™ intracardiac injection for both safety and efficacy. Future positive results could position Longeveron as a leader in the field, with the hope of saving the lives of many infants through this novel therapy. Keep up to date with Longeveron’s cell-based therapies on its website www.longeveron.com. We are a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions.Our lead investigational product is Lomecel-B™, which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. We believe that by using the same cells that promote tissue repair, organ maintenance, and immune system function, we can develop safe and effective therapies for some of the most difficult diseases and conditions associated with aging. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Christine Petraglia - TraDigital IR +1 844-470-2550 christine@tradigitalir.com Company Website https://longeveron.com/

July 07, 2023 09:00 AM Eastern Daylight Time

NanoViricides Inc. (NYSE American: NNVC) Begins Long-Awaited Clinical Trials For Its Anti-Viral Nanomedicine NV-CoV-2, Oral, Amid Continuing Need For COVID Treatment

NanoViricides, Inc.

By David Willey, Benzinga Read the latest report on NanoViricides here. NanoViricides (NYSE American: NNVC) is a drug development company working on a novel nanomedical treatment. It recently updated the world on the status of its long-awaited and now active trials into its lead drug candidate, NV-CoV-2. “NV-CoV-2, the Company’s lead drug candidate for the treatment of coronavirus infections including COVID and potentially many cases of long COVID, has entered human clinical trials initiated by the Drug Sponsor Karveer Meditech Pvt. Ltd. India, the Company’s Licensee and co-developer in India,” announced the Company. NanoViricides is developing cutting-edge nanomedicine treatments, which use their special nanomicelles’ ability to directly attack and destroy the virus particles. To do this, the nanoviricides mimick the receptor site on the cell to which the virus binds. No matter how many variants develop, this site remains the same, so the virus is unlikely to escape the nanoviricide drug. The Company’s drug candidate NV-CoV-2 uses the company’s patented nanoviricide platform technology, which uses novel mechanisms to fight COVID-19 and potentially all other human coronaviruses. The Need For A Lasting Coronavirus Treatment As the company races to develop its leading drug, there remains a significant need to develop safe and lasting treatments for COVID-19 and other coronaviruses. It has been estimated that by the end of the four-year period from January 2020 to December 2023, the COVID-19 pandemic will have cost the American economy up to $14 trillion. Furthermore, it is estimated that 65 million people still suffer from “long COVID,” the continuation of coronavirus symptoms for months after clinically the infection itself has subsided. Symptoms of long Covid can range from mild to severe, and the case numbers of those with long Covid are continuing to increase. Could NV-CoV-2 Be Used For Future Pandemics? Then there are the risks of other coronaviruses and future pandemics. A prediction from the disease research group Metabiota, says that there is a 47% - 57% likelihood that another pandemic as serious as COVID-19 could occur within the next 25 years. This is why NanoViricides believes it is important to develop a drug that is safe and effective for treating a wide range of patients. Its drug candidate NV-CoV-2 has oral formulations for milder cases and an injectable solution for more severe patients. The company is focusing its attention on treatment for COVID-19 for now, but the innovative nanomedicine could even be a broad-spectrum antiviral for treating diseases beyond COVID-19. “We believe these clinical trials are an important milestone not only for NanoViricides and Karveer Meditech, India, but also for the advancement of treatments against all viral infections worldwide,” said Dr. Anil Diwan, Ph.D., President and Executive Chairman of the Company, explaining, “NV-CoV-2 is aimed at satisfying the as-yet-unmet medical need of a highly effective broad-spectrum, anti-coronavirus drug that can be used for all patient populations. Moreover, it brings into the clinic a novel platform technology of attacking viruses to develop highly effective antiviral drugs.” Treatments for COVID-19 currently on the market include Molnupiravir from Merck & Co. (NYSE: MRK), Paxlovid from Pfizer Inc. (NYSE: PFE) and Remdesivir from Gilead Sciences, Inc. (NASDAQ: GILD), though there are problems or limitations with each of these options, and the multi-billion-dollar market remains wide open for a new effective treatment. The overall antiviral market is projected to surpass around $71.1 billion by 2032. Learn more about how NanoViricides is tackling coronaviruses by visiting its website. About NanoViricides NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. In addition, we are developing a clinical candidate for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. The Company cannot project an exact date for filing an IND for this drug because of its dependence on a number of external collaborators and consultants.The Company is now working on tasks for completing an IND application. The Company is currently pursuing two separate drug candidates for the treatment of COVID-19 patients. NV-CoV-2 is our nanoviricide drug candidate that does not encapsulate Remdesivir. NV-CoV-2-R is our other drug candidate that is made up of NV-CoV-2 with Remdesivir encapsulated in it. The Company believes that since Remdesivir is already US FDA approved, our drug candidate encapsulating Remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.The Company intends to re-engage into an IND application to the US FDA for NV-HHV-101 drug candidate for the treatment of shingles once its COVID-19 project moves into clinical trials, based on resources availability. The NV-HHV-101 program was slowed down because of the effects of recent COVID-19 restrictions, and re-prioritization for COVID-19 drug development work.The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for poxviruses if the initial research is successful. The Company's technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Contact Details NanoViricides, Inc. +1 203-937-6137 info@nanoviricides.com Company Website http://www.nanoviricides.com

July 06, 2023 09:00 AM Eastern Daylight Time

Graft Polymer kicking off the second half with plant commissioning

Graft Polymer (UK) PLC

Graft Polymer (UK) PLC (LSE:GPL) independent non-executive director Alex Brooks speaks to Thomas Warner from Proactive after the polymer modification company announced the commissioning of its bespoke production equipment site in Slovenia later this month. Brooks puts the announcement in its context and describes it as "the culmination of the efforts that began with the IPO process." He also gives an overview of how the business performed during the first half of 2023 and discusses plans for the long-term future of the company. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

July 06, 2023 05:51 AM Eastern Daylight Time

Video

News Release

Spectral MD's DeepView Imaging Technology revolutionizing wound healing with Artificial Intelligence

Spectral MD Holdings Ltd

Spectral MD Holdings COO Niko Pagoulatos joined Proactive's Natalie Stoberman to share how the company plans to progress after receiving a recommendation for ISO 13485 certification. Spectral MD develops technology using predictive analytics and AI algorithms to help clinicians make more accurate and faster treatment decisions. There are no diagnostic imaging devices that provide clinicians with an objective and immediate assessment of a wound’s healing potential. Spectral MD’s DeepView Technology provides an informed solution for clinicians and allows for a clear picture of the wound to be established prior to treatment or other interventions. DeepView is a portable imaging platform that allows for immediate wound healing assessment and provides clinicians with physiological information that is not visible to the human eye. Contact Details Proactive USA +1 347-449-0879 na-editorial@proactiveinvestors.com

July 05, 2023 05:37 PM Eastern Daylight Time

Video

NextFerm Technologies announces a commercial manufacturing agreement for the production of ProteVin™, its vegan protein, with Kothari Fermentation and Biochem, a subcontractor in India

NextFerm Technologies Ltd.

In the first stage, the production setup will enable an annual production capacity of $4M in revenues The completion of the production setup is expected during the fourth quarter, 2023 (Yokneam Illit, July 5, 2023) – NextFerm Technologies Ltd. (TASE:NXFR), a food-tech company developing ProteVin™, a vegan, fermentation-based, non-GMO protein alternative and other innovative yeast-based nutrients, announced today that it has entered into a commercial manufacturing agreement with a subcontractor in India, Kothari Fermentation and Biochem, for the production of ProteVin™. The agreement relates only for production services and doesn’t include IP transfer to the subcontractor. The company's management has worked diligently to find a solution to establish a production setup that will be in line with its financial means, so that, in this stage, this agreement replaces the establishment of the manufacturing plant with the subcontractor in North Macedonia, and will allow the company to supply market demands with a lower investment than planned and with the ability to increase future capacity. In the first stage, the production setup will enable an annual production capacity of $4M in revenues. In addition to the production equipment that the company has purchased so far, the Company estimates that the necessary investment needed for the completion of the production setup and the purchase of the production equipment for the first stage will be approximately $2M. This investment will be financed from the company's own resources. The completion of the production setup is expected during the fourth quarter, 2023. The building in which the production facility is planned to be built already exists and has needed utilities, and most of the equipment needed to operate it has already been purchased by the company and/or is in the possession of the subcontractor and is available for the company’s use. Starting 2023, five food and dietary supplement companies in the USA and Europe have launched vegan products based on ProteVin, including Swanson, one of the leading and veteran nutritional supplement brands in the USA, Spacemilk and Mushroom Design. In the five products, the ProteVin™ brand is labeled on the packaging. The company has a wide and growing base of food and dietary supplement companies, including global companies, that are examining ProteVin for use in a variety of alternative products. In addition to ProteVin, the production facility in India will allow the company to also produce and market the by-product Yeast Extract, which is obtained in the production process of the protein. This product is an ingredient that enhances taste and flavor in the food industry. The company has developed a first generation of Yeast Extract based on a unique technology developed by the company (a yeast strain and unique processes) that contributes to the quality of the Yeast Extract products and the profitability of these products. The Yeast Extract market is estimated at approximately $1.9 Billion in global annual sales, with a growth of approximately 8.7% which is influenced, among others, by the growth of the alternative food market[1]. This is one of the most important and largest categories in the flavors market. Boaz Noy, Chief Executive Officer of NextFerm, said: "In past few months, we have focused on finding an efficient and flexible production alternative to the production facility that was planned to be established in North Macedonia, which will be in line with the company's capabilities and financial resources. The production setup that will be established in India will allow us to meet the growing demand for ProteVin, with a lower investment than planned with the ability to increase future capacity. ProteVin™ is the only alternative protein on the market today with a neutral taste and an animal-like nutritional value, and we believe it will become a leading solution in the global alternative protein industry. In addition, the company will be able to initiate the production and launch of Yeast Extract, which is a vegan food ingredient that enhances taste and flavor and with a high and growing demand in the food industry." About Kothari Fermentation and Biochem Kothari Fermentation and Biochem, traded on the Bombay Stock Exchange (BSE:KFBL.BO) is a manufacturer of baker’s yeast, Instant Yeast, Active & Inactive Dried Yeast, Cell walls, yeast extract, alcohol yeast and other yeast based products. For more information, visit the Kothari website at: www.kothariyeast.in About NextFerm Technologies NextFerm Technologies, traded on the Tel Aviv Stock Exchange (TASE:NXFR) is a food-tech company engaged in the research, development, manufacturing and marketing of innovative, functional and vegan yeast-derived, non-GMO protein alternatives for various applications in the food and food supplement markets and the growing market for animal-derived protein alternatives. NextFerm's flagship product is ProteVin™, a vegan, yeast-derived protein with animal-like nutritional value (Amino acid profile BCAA=21%, Leucine=9%, EAA=53% and high digestibility PDCAAS=1) and a neutral flavor. ProteVin™ is designed for a variety of categories in the alternative protein market, which is estimated at USD 20 billion in terms of final products and at USD 3.5 billion in terms of raw materials with an annual growth rate of above 20%, including milk and dairy substitutes, meat substitutes and additional categories such as infant nutrition, adult nutrition, and sports nutrition. The Company launched ProteVin™ and initiated marketing and supplying the product in second quarter of 2022. For more information, visit the NextFerm website at: www.nextferm.com [1] https://www.fortunebusinessinsights.com/yeast-extract-market-106656 Legal Notice Regarding Forward-Looking Statements This announcement also includes forecasts, projections, assessments, estimates and other information which refer to future events and matters, the realization of which is uncertain and not exclusively under the Company’s control (forward-looking information). The main facts and data used to support this information are facts and data regarding the current position of the Company and its businesses (including the scope of sales and levels of profitability, manpower, commercial engagements and more), facts and data regarding the current global position of the Company’s operating segments (including industry-specific financial developments, environmental regulatory developments, the competitive environment, technological developments, the reinsurance market and more), and macro-economic facts and data (including the economic situation both in Israel and around the world, yields in the capital markets, social and state developments and more), all as known by the Company when publishing this announcement. The forward-looking information included above in this announcement is significantly based upon, in addition to the existing information held by the Company, on the Company’s current assessments and expectations of future developments vis-a-vis each one of the aforementioned parameters, and the interconnectedness of each one of these developments. The Company has no certainty that its forecasts and assessments will indeed eventuate, and the Company’s operating results may be materially different than the results assessed or implicit based on that set forth above, inter alia, as a result of a change in any of the aforementioned factors. Contact Details NextFerm Technologies Ltd. Yossi Ohana - CFO +972 54-771-5893 yossio@nextferm.com Investor and Media Contact Meirav Gomeh-Bauer +972 54-476-4979 meirav@bauerg.com

July 05, 2023 03:06 PM Eastern Daylight Time

Auri Inc. – Dividend, Retirement Timelines and Expectations

Auri, Inc.

Auri Inc. (OTC: AURI ) (“AURI”) (the “Company”) is proud to announce a dividend of AURI Tokens 1 to 200 for every single share owned of AURI stock. Along with the retirement of 300 million shares of stock returned to treasury from the out standing shares and 9 billion shares reduced from the Authorized shares. The CEO Edward Vakser goes on to state: “The company has worked a very long time to bring the right pieces to the table at the right time. We are excited to finally show shareholders what we have been working for. The over all value is far a fields stronger than it was even a year ago! We are excited to give a piece of the pie back to shareholders who have waited through this long journey. We as a company are now focused on share structure reductions, reporting preparation for SEC reporting status, and sales growth for our products, and services.” Dividend Information The company recently posted a ruling given to OTC markets by FINRA regarding trading rights to OTCMarkets for digital currencies. The company will have an ex dividend date of October 02, 2023. Outstanding Share Retirement expectations The company will be returning to treasury shares up to at least 1 billion shares from the outstanding stock. We will be conducting this in at least 3-4 blocks between July 3, 2023 and August 10, 2023. Authorized Share Reduction expectations The company is obligated to retire 10 billion shares from the Authorized common stock according to its acquisition contract with Apex Farms Corp. for the 2 US patents it acquired along with marketing materials, media, and data. The company will conduct the retirements in 2 tranches. The first tranche will be 9 billion shares approved by the company on July 1, 2023. However the last 1 billion shares from the Authorized shares will be retired once the Outstanding shares returns to below 3 billion shares. Our plan is to retire the last 1 billion shares prior to close of Q3 2023. Recent Acquisitions Recently the company has acquired Aqua Vertical Farms Inc. a Wyoming corporation via 100% control. The company has launched the website for its newly acquired patents www.aquavertical.com as well as launched pre-orders for the residential systems. About the Hydroponics Vertical Farming system The consumer systems allow the grower to grow up to 45 full size plants in a 13 square foot area. The systems boast water control valves for greater control of water flow, the ability to be connected to a water timer, and the ability to be used hydroponically with fish! The system is the perfect small growing system for the back yard or porch! Edward Vakser goes on to say “we are excited to be launching this product and for a limited time From July 1, 2023 to July 31, 2023 Auri Inc will be matching buyers of the system with up to $250 of Auri Token for every purchase!’ About The Patents Acquisition Auri Inc. has signed an acquisition agreement with Apex Farms Corp which is in the middle of liquidation of its remaining assets for the 2 US patents No.’s 9,795,097 and 10,004,188. The company has paid common shares for said patents. However Apex Farms Corp. had several negotiable terms set forth in the contract to bring more value to AURI in the process. Buyer agrees to retire 1 billion shares from the O/S within 30 days of close of this agreement. Buyer agrees to not issue more shares through the Regulation A+ tier 1 post date of May 23, 2023 Buyer agrees to comply and produce PCAOB Audits within 160 days of May 23, 2023 Buyer agrees after closing the Regulation A+ Tier 1 the Authorized shares will be reduced to 3 billion or less but can be raised again for an S-1 Registration. About patent No.’s 9,795,097 and 10,004,188 These patents were invented by Justin Williams and Alexander M. Woods-Leo and the venture started in 2013. The patents are in reference to A-Frame technology and are primarily designed as Outdoor/Indoor systems. The goal of this technology was to allow farmers to buy 1 row and scale up as the farmer made money from the system without having to buy an entire indoor facility. However the system was designed to be optimal in greenhouses. Auri Inc. wishes to explain the patents at the time of closing are owned by Apex Farms Corp. Recently the company announced following: The company and its management are excited to welcome the long-awaited news from FINRA regarding trading digital assets such as crypto currencies, NFT’s and other Digital Securities. We see the future, and so do FINRA and OTC Markets. Allowing OTC Markets to trade digital securities and crypto currencies adds value and opportunities to any company that can deliver and trade their NFT’s and Tokens as an added value to its shareholders. https://securities-law-blog.com/2023/06/27/finra-approves-otc-markets-to-trade-digital-securities/ About Auri Inc. AURI Inc. as good as gold! The Company was formed by a group of investors whose talents and interests were based in Production, Content Development, Audio/Visual Presentations, Intellectual Properties Development, and acquisitions, as well as oil and gas and real-estate investments. The company launched its own Crypto Currency, www.Auritoken.io and has licensed its Art Inventory at nft/blackdracos.com. The management is based around seasoned corporate officers, directors and consultants who are experienced in management and mergers/acquisitions of multimillion dollar companies. The company's plan and concept were developed and based around a plan of acquiring and developing High End Art and Reproductions, backed by AURI Gold Crypto Currency, focusing AURI INC to become a Publisher and Licensor as well as NFT developer. Then, retaining the duplication and reproduction rights, on an exclusive basis, in order to sell and distribute the products worldwide. The company and management believe that they can create, sustain and grow one of the largest art publishing companies in the world. AURI Inc., also owns a "wholly owned subsidiary": EVAP Inc. Evap Inc. has patent pending technology to assist with one of the biggest issues in the oil and gas industry, "PRODUCED WATER". The technology can take produced saltwater and turn it into a steam cleaner than most cities tap water by removing most of the metals and suspended solids. Safe Harbor Statement: This release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate", "project", "intend", "forecast", "anticipate", "plan", "planning", "expect", "believe", "will likely", "should", "could", "would", "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, and domestic or global economic conditions -- activities of competitors and the presence of new or additional competition and conditions of equity markets. Press Contact info: Mark2media Group auriincpr@gmail.com (302) 261-9663 Twitter: @AURI_OTC LinkedIn: https://www.linkedin.com/company/auri-inc/ FB: https://www.facebook.com/profile.php?id=100057444009513 TikTok: https://www.tiktok.com/@auri_otc?_t=8deaRcgzNs6&_r=1 Contact Details Mark2media Group auriincpr@gmail.com

July 05, 2023 08:45 AM Eastern Daylight Time

US radiologists working with Nutex Health Hospitals now have access to world-class DrAid™, an artificial intelligence doctor’s assistant

Vingroup

HANOI, VIETNAM - Media OutReach - 3 July 2023 - VinBrain's advanced AI assistant in diagnostic imaging, DrAid™ Chest XR, was successfully integrated into the radiology workflow of Nutex Health Inc. in Houston, Texas, United States through a Software Subscription License Agreement – SaaS (Software as a Service) model. Nutex Health Inc. is a physician-led healthcare organization with 19 hospitals across 8 states, focusing on functional emergency care and primary care. With a revenue of USD219.2 million in the fiscal year 2022, Nutex Health Inc. has recognized the positive impact of DrAid™ during its 90-day trial, particularly in the ER department's radiology care pathway (Emergency Radiology). DrAid™ CXR employs AI algorithms to prioritize and triage abnormalities in chest X-rays with an impressive accuracy rate of 91%. Integrating DrAid™ Chest XR into Nutex Health facilities allows for the timely identification and prioritization of time-sensitive findings in chest X-rays. Furthermore, it assists in clinical management and reduces the chances of errors or delays in reporting. Within a year of receiving the first FDA 510(k) clearance last September, DrAid TM successfully secured commercialization in the United States for its AI-enabled Radiology v1. This rapid achievement highlights the efficiency and effectiveness of the system in detecting suggestive pneumothorax findings in human chest X-rays. Dr. Tom Vo, CEO & Chairman of Nutex Health Inc., commended DrAid™ CXR for its remarkable impact, stating, " The software is a high-standard product capable of identifying abnormalities in chest X-rays." By this, DrAid™ CXR enhances the probability of confirming a case and saves valuable time for doctors, especially during odd or late-night hours in time-sensitive settings like the ER departments. Dr. Vo concluded, " We selected a great AI company to optimize the service workflows of our ER hospitals. " Mr. Steven Truong, VinBrain’s Chief Executive Officer, expressed his thoughts on this deployment: “This collaboration represents the integration of innovative medical infrastructure in micro-hospitals, aligning with the global healthcare industry's ongoing transformation towards AI-powered solutions”. VinBrain persists in challenging markets like the US while developing new AI products to combat global diseases. In June, their DrAid™ Liver Cancer CT gained recognition at the esteemed 4th Stanford AIMI Symposium (USA) and the 10th Radiological Congress of Ho Chi Minh City, Vietnam. Liver cancer accounted for 905,677 new cases and 830,180 deaths in 2020, with a projected risk for over 90 countries and 30 million lives by 2040. VinBrain remains committed to addressing this pressing global health issue. VinBrain's innovative platform employs advanced AI technology for rapid and accurate identification of abnormal liver lesions. It not only facilitates the detection of cancerous growths but also delivers precise quantitative measurements of lesion volume and diameter, even for tumors as small as 5mm. At the 10th Radiological Congress of Ho Chi Minh City, Nguyen Minh Duc, MD, Ph.D., Head of the Scientific Committee at Pham Ngoc Thach University of Medicine in Vietnam, and Deputy Editor of Radiology Case Reports, commended “This exceptional medical imaging innovation developed by skilled Vietnamese professionals highlights VinBrain's proficiency in the AI era. The technology holds promise for assisting oncologists in assessing liver cancer and has the potential to expand its application to other types of cancer.” During his recent visit to VinBrain's office in Hanoi, Vietnam, Gregory Moore, MD, Ph.D., Corporate Vice President of Microsoft Health and Adjunct Clinical Professor of Radiology at Stanford University School of Medicine, who holds a Radiological Sciences Ph.D. from MIT and specializes in Neuroradiology, expressed his admiration for VinBrain. He remarked, "I am inspired by how VinBrain has swiftly responded to the pressing needs by overcoming obstacles, embracing cutting-edge technology, and delivering a positive impact to the healthcare ecosystem in Vietnam, Southeast Asia, and now, with their first FDA approval, in the United States." He further described VinBrain as a trailblazing health tech company that generates contagious momentum. Nutex Health Inc. Nutex Health Inc. (NASDAQ: NUTX) is a US-based for-profit healthcare delivery system headquartered in Houston, Texas. The company operates in two divisions: The Hospital Division and the Population Health Management Division. Currently, the Hospital Division owns and operates 19 facilities across eight states, and there are plans for an additional 14 facilities shortly. VinBrain VinBrain is a startup that has been operating for four years and is backed by Vingroup, the largest conglomerate in Vietnam. The company aims to integrate AI and IoT technologies to enhance people's lives and productivity. With an impressive portfolio of cutting-edge tech products and platforms, such as DrAid™ and AIScaler™, VinBrain has developed more than 300 AI models specifically designed for processing medical images. These models have been built using a dataset that comprises over 2.5 million images and extensive text-based big data from Vietnam, the USA, and India. One of VinBrain's notable achievements is the deployment of DrAid™, a comprehensive AI platform for diagnostic radiology, in over 100 hospitals across Vietnam, Myanmar, New Zealand, and the USA. Contact Details VinBrain Hang Vu, Chief Marketing Officer +84 90 393 12 46 hang.vu@vinbrain.net Company Website https://draid.ai

July 03, 2023 09:30 AM Eastern Daylight Time

Image

Creo Medical Group "looking very well" - Proactive Research Analyst

Creo Medical Group PLC

Proactive Research Analyst Daniel Appiah gives the highlights from his latest research note on UK-based medical device company Creo Medical Group PLC (AIM:CREO). Creo recently announced that the medical device company's Speedboat Inject product was used for the first time in an upper gastrointestinal (GI) procedure in Europe, a major milestone for the business. Appiah says Creo is "looking very well" and gives his take on what recent developments are likely to mean for the company's financials. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

July 03, 2023 09:09 AM Eastern Daylight Time

Video

1 ... 59 60 61 62 63 ... 171